Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Nov 28, 2022 5:30pm
141 Views
Post# 35135096

RE:Biogen’s Alzheimer’s woes

RE:Biogen’s Alzheimer’s woesYa - seems that brain swelling is also an issue with this drug.

Exactly why I prescribe to a future of reducing inflammation and reduced neuroinflammation via H2S gaseous mediatioin.

A healthier approach.

Unfortunately, that's not immediately a high priority ...

1. pain and inflammation in the gut - painkillers
2. pain and inflammation in the gut - irritable bowel disease and other autoimmune diseases
3. spread of inflammation to the respiratory tract
4. then - only then - might we be ready to attack neuroinflammation specifically (~2030+)

Years away in terms of a better approach - safer approach - and healthier living that leads to less problems.

For now - keep growing Exelon as a more cost-effective approach in a world where AD isn't well understood - or - isn't well handled.

IMO
<< Previous
Bullboard Posts
Next >>